Association of polypharmacy and potential drug-drug interactions with adverse treatment outcomes in older adults with advanced cancer.
Mostafa R S MohamedSupriya G MohileKatherine M JubaHala AwadMegan WellsKah Poh LohMarie FlanneryEva CulakovaRachael G TylockErika E RamsdalePublished in: Cancer (2023)
In a cohort of older adults with advanced cancer, polypharmacy and PDIs were associated with an increased risk of adverse treatment outcomes. Providing meaningful screening and interventional tools to optimize medication use may improve treatment-related outcomes in these patients.
Keyphrases
- advanced cancer
- palliative care
- adverse drug
- end stage renal disease
- physical activity
- ejection fraction
- chronic kidney disease
- newly diagnosed
- prognostic factors
- emergency department
- type diabetes
- patient reported outcomes
- human health
- replacement therapy
- insulin resistance
- skeletal muscle
- drug induced
- patient reported
- electronic health record